120 related articles for article (PubMed ID: 1780688)
1. Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma.
Gion M; Mione R; Tremolada C; Dalla Palma P; Ruol A; Dittadi R; Leon A; Nosadini A; Castoro C; Bruscagnin G
Scand J Clin Lab Invest Suppl; 1991; 207():37-41. PubMed ID: 1780688
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
3. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Rapellino M; Pecchio F; Baldi S; Adamo MR; Macri M; Ricardi G
Scand J Clin Lab Invest Suppl; 1991; 207():47-9. PubMed ID: 1780690
[TBL] [Abstract][Full Text] [Related]
5. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
[TBL] [Abstract][Full Text] [Related]
6. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
7. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer.
Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F
Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of TATI and other markers in solid tumors.
Taccone W; Mazzon W; Belli M
Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
[TBL] [Abstract][Full Text] [Related]
10. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
11. Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Klockars M; Pettersson T; Fröseth B; Selroos O; Stenman UH
Chest; 1990 Nov; 98(5):1159-64. PubMed ID: 2225961
[TBL] [Abstract][Full Text] [Related]
12. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer.
Pectasides D; Economides N; Bourazanis J; Pozadzizou P; Gogou L; Koutsiouba P; Athanassiou A
Am J Clin Oncol; 1994 Aug; 17(4):307-12. PubMed ID: 8048392
[TBL] [Abstract][Full Text] [Related]
13. [Serum tumor markers SCC, TATI and TPS: value in follow-up of females with cervix cancer].
Joura E; Gitsch G; Kainz C; Fröhlich B; Biegelmayr C; Kölbl H
Gynakol Geburtshilfliche Rundsch; 1992; 32 Suppl 1():115. PubMed ID: 1286308
[No Abstract] [Full Text] [Related]
14. Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer.
Pectasides D; Bourazanis J; Economides N; Pozadzidou P; Gogou L; Koutsiouba P; Athanassiou A
Int J Biol Markers; 1993; 8(2):81-7. PubMed ID: 8366300
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
17. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the tumor-associated trypsin inhibitor (TATI) marker in patients with carcinoma of the uterine body 17 years after treatment.
Kozakiewicz B; Chadzyńska M; Dmoch-Gajzlerska E
Eur J Gynaecol Oncol; 2014; 35(1):39-43. PubMed ID: 24654459
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]